UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Datensatz exportieren als...
BibTeX
Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer
Radiology, 2019-12, Vol.293 (3), p.531-540
Sumkin, Jules H
Berg, Wendie A
Carter, Gloria J
Bandos, Andriy I
Chough, Denise M
Ganott, Marie A
Hakim, Christiane M
Kelly, Amy E
Zuley, Margarita L
Houshmand, Golbahar
Anello, Maria I
Gur, David
2019
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Sumkin, Jules H
Berg, Wendie A
Carter, Gloria J
Bandos, Andriy I
Chough, Denise M
Ganott, Marie A
Hakim, Christiane M
Kelly, Amy E
Zuley, Margarita L
Houshmand, Golbahar
Anello, Maria I
Gur, David
Titel
Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer
Ist Teil von
Radiology, 2019-12, Vol.293 (3), p.531-540
Ort / Verlag
United States
Erscheinungsjahr
2019
Quelle
MEDLINE
Beschreibungen/Notizen
Background Staging newly diagnosed breast cancer by using dynamic contrast material-enhanced MRI is limited by access, high cost, and false-positive findings. The utility of contrast-enhanced mammography (CEM) and Tc sestamibi-based molecular breast imaging (MBI) in this setting is largely unknown. Purpose To compare extent-of-disease assessments by using MRI, CEM, and MBI versus pathology in women with breast cancer. Materials and Methods In this HIPAA-compliant prospective study, women with biopsy-proven breast cancer underwent MRI, CEM, and MBI between October 2014 and April 2018. Eight radiologists independently interpreted each examination result prospectively and were blinded to interpretations of findings with the other modalities. Visibility of index malignancies, lesion size, and additional suspicious lesions (malignant or benign) were compared during pathology review. Accuracy of index lesion sizing and detection of additional lesions in women without neoadjuvant chemotherapy were compared. Results A total of 102 women were enrolled and 99 completed the study protocol (mean age, 51 years ± 11 [standard deviation]; range, 32-77 years). Lumpectomy or mastectomy was performed in 71 women (79 index malignancies) without neoadjuvant chemotherapy and in 28 women (31 index malignancies) with neoadjuvant chemotherapy. Of the 110 index malignancies, MRI, CEM, and MBI depicted 102 (93%; 95% confidence interval [CI]: 86%, 97%), 100 (91%; 95% CI: 84%, 96%), and 101 (92%; 95% CI: 85%, 96%) malignancies, respectively. In patients without neoadjuvant chemotherapy, pathologic size of index malignancies was overestimated with all modalities ( = .02). MRI led to overestimation of 24% (17 of 72) of malignancies by more than 1.5 cm compared with 11% (eight of 70) with CEM and 15% (11 of 72) with MBI. MRI depicted more ( = .007) nonindex lesions, with sensitivity similar to that of CEM or MBI, resulting in lower positive predictive value of additional biopsies (13 of 46 [28%; 95% CI: 17%, 44%] for MRI; 14 of 27 [52%; 95% CI: 32%, 71%] for CEM; and 11 of 25 [44%; 95% CI: 24%, 65%] for MBI (overall = .01). Conclusion Contrast-enhanced mammography, molecular breast imaging, and MRI showed similar detection of all malignancies. MRI depicted more nonindex suspicious benign lesions than did contrast-enhanced mammography or molecular breast imaging, leading to lower positive predictive value of additional biopsies. All three modalities led to overestimation of index tumor size, particularly MRI. © RSNA, 2019
Sprache
Englisch
Identifikatoren
ISSN: 0033-8419
eISSN: 1527-1315
DOI: 10.1148/radiol.2019190887
Titel-ID: cdi_pubmed_primary_31660801
Format
–
Schlagworte
Adult
,
Aged
,
Breast Neoplasms - diagnostic imaging
,
Contrast Media
,
Female
,
Humans
,
Magnetic Resonance Imaging
,
Mammography
,
Middle Aged
,
Molecular Imaging
,
Neoplasm Staging
,
Prospective Studies
,
Radiopharmaceuticals
,
Sensitivity and Specificity
,
Technetium Tc 99m Sestamibi
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX